Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Radiosurgery 12Temozolomide 10Radiotherapy 10Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 6Bevacizumab 6Surgical Procedures, Operative 5Pemetrexed 5Gefitinib 5Drug Therapy 5Carboplatin 5pyrotinib 4icotinib 4aumolertinib 4Trastuzumab 3Spermine Synthase 3Radiation 3Lomustine 3Etoposide 3Dexmedetomidine 3Chlorotoxin 3Carmustine 3osimertinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thiotepa 2Surveys and Questionnaires 2Sevoflurane 2Propofol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Brain Neoplasms × neratinib × Clear all
NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
120 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡